Novel therapeutic agents for the treatment of myelodysplastic syndromes

Seminars in Oncology

Volumn 27, Issue 5, 2000, Pages 560-577

  Cheson, B D ^a   Zwiebel, J A ^a   Dancey, J ^a   Murgo, A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 5 AZA 2' DEOXYCYTIDINE; 7 HYDROXYSTAUROSPORINE; ACYLTRANSFERASE INHIBITOR; AMIFOSTINE; ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BENZAMIDE DERIVATIVE; BMS 214662; CYCLOPHOSPHAMIDE; CYTARABINE; DEPSIPEPTIDE; DNA TOPOISOMERASE INHIBITOR; DOLASTATIN 10; IMMUNOSUPPRESSIVE AGENT; MS 27275; PROTEIN FARNESYLTRANSFERASE INHIBITOR; R 115777; THALIDOMIDE; ZIDOVUDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CONFERENCE PAPER; DRUG MECHANISM; HUMAN; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; STANDARDIZATION;

ANTINEOPLASTIC AGENTS; HUMAN; MYELODYSPLASTIC SYNDROMES;

EID: 0033785219     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (192)

1. Proposals for the classification of the myelodysplastic syndromes
2. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British group
3. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
4. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting - Airlie House, Virginia
5. Prognostic factors in the myelodysplastic syndromes: Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosome analysis
6. Preleukaemia: A long-term prospective study of 326 patients
7. Myelodysplastic syndromes: A study of 101 cases according to the FAB classification
8. Utility of the FAB classification for myelodysplastic syndromes: Investigation of prognostic factors in 237 cases
9. Chronic myelodysplastic syndrome: Short survival with or without evolution to acute leukaemia
10. Therapyrelated leukemia and myelodysplastic syndrome: Clinical, cytogenetic, and prognostic features
11. International scoring system for evaluating prognosis in myelodysplastic syndromes
12. Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults
13. Differentiation of myeloid leukaemic cells: New possibilities for therapy
14. Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia
15. Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside
16. Low-dose cytosine arabinoside in the treatment of acute nonlymphoblastic leukemia and myelodysplastic syndromes
17. Low dose ara-C for patients with myelodysplastic syndromes
18. Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia
19. Low dose cytosine arabinoside (ara-C) in myelodysplastic syndromes
20. Low-dose cytosine arabinoside (ara-C) therapy in the myelodysplastic syndromes and acute leukemia
21. Response of preleukemic syndromes to continuous infusion of low-dose cytarabine
22. Treatment of leukemia with low-dose ara-C: A study of 160 cases
23. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes
24. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: A review of 20 years' experience
25. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study
26. Oral idarubicin (IDA) for RAEB, RAEBt, and acute leukemia (AL) post myelodysplastic syndrome (MDS). A phase II open study
27. Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin
28. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia
29. Treatment of myelodysplastic syndromes with low-dose oral 6-thioguanine
30. Phase II trial of homoharringtonine (HHT) in patients with myelodysplastic syndromes (MDS)
31. Topotecan, a topoisomerase I inhibitor is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia
32. Topotecan and cytatabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
33. A new combination chemotherapy using topotecan, fludarabine, ara-C and G-CSF for aggressive myelodysplastic syndromes and acute myelogenous leukemia in the elderly: Dose finding for topotecan study
34. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
35. Phase II study of amifostine in patients with myelodysplastic syndromes (MDS): Impact on hematopoiesis
36. Treatment of myelodysplastic syndrome with amifostine and its effect on hematopoiesis
37. Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients
38. Effect of treatment with amifostine used as single agent in patients with refractory anemia on clinical outcome and serum TNFα levels
39. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
40. A synthetic inhibitor of histone deacetylase, MS-27- 275, with marked in vivo antitumor activity against human tumors
41. Biochemistry of azacitidine: A review
42. Kinetics of phosphorylation of 5-aza-2'-deoxycytidine by deoxycytidine kinase
43. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine
44. 5-Azacytidine, DNA methylation, and differentiation
45. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60)
46. 5-aza-2'-Deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends
47. DNA methylation changes in hematologic malignancies: Biologic and clinical implications
48. DNA methylation
49. 5-Azacytidine (NSC 102816): A new drug for the treatment of myeloblastic leukemia
50. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia. A Southwest Oncology Group study
51. Azacytidine: 10 years later
52. Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings
53. 5-Azacytidine in acute leukemia
54. Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes
55. 5-Azacytidine (AZ) as a low dose continuous infusion is an effective therapy for patients with myelodysplastic syndromes (MDS)
56. Trilineage (TLR) response of myelodysplastic syndromes (MDS) to subcutaneous (SQ) azacytidine (Aza C)
57. A randomized controlled trial of subcutaneous azacitidine (AZA C) in patients with the myelodysplastic syndrome (MDS): A study of the Cancer and Leukemia Group B (CALGB)
58. The impact of 5-azacytidine on the quality of life of patients with the myelodysplastic syndrome (MDS) treated in a randomized phase III trial of the Cancer and Leukemia Group B (CALGB)
59. Phase I-II clinical-biological study of 5-aza-2'-deoxycytidine (5azaCdR) as a differentiation inducer in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) of the elderly
60. Continuous infusion of low-dose 5-aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome
61. Nuclear receptor repression mediated by a complex containing SMRT, mSin 3A, and histone deacetylase
62. Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity
63. Role of the histone deacetylase complex in acute promyelocytic leukaemia
64. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
65. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL
66. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein
67. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARatpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
68. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO
69. ETO a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin 3 corepressors
70. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
71. Alterations in DNA methylation: A fundamental aspect of neoplasia
72. Transcriptional repression by the methyl-CpG-binding protein MeCP 2 involves a histone deacetylase complex
73. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
74. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
75. Treatment of episodic hyperammonenia in children with inborn errors of urea synthesis
76. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: A clinical trial
77. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase
78. Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes Memorial Lecture
79. Phenylacetate and derivatives as novel, nontoxic chemopreventive agents
80. Phenylacetate and derivatives: Simple compounds with complex antitumor activities
81. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs
82. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate
83. Sodium butyrate inhibits histone deacetylation in cultured cells
84. The effect of sodium butyrate on histone modification
85. Selective activity of phenylacetate against malignant gliomas: Resemblance to fetal brain damage in phenylketonuria
86. Enhancement of tumor immunogenicity by phenylacetate and derivatives: Changes in surface antigens and tumor-derived immunosuppressive factors
87. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate
88. Phenylacetate and phenylbutyrate promote cellular differentiation in human prostate cancer systems
89. Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells
90. Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid
91. Action of FR901228, a Novel Antitumor Bicyclic Depsipeptide Produced by Chromobacterium violaceum no. 968, on Ha-ras Transformed NIH 3T3 Cells
92. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
93. Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells
94. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: A phase II clinical trial with a differentiation-inducing agent
95. Cloning of the cDNA encoding phenylalanyl tRNA synthetase regulatory alpha-subunit-like protein whose expression is down-regulated during differentiation
96. Drugs used in the chemotherapy of protozoan infections
97. Delicious poison: Arsenic trioxide for the treatment of leukemia
98. Arsenic trioxide treated 72 cases of acute promyelocytic leukaemia
99. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
100. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
101. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner
102. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells
103. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
104. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids
105. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
106. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms
107. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells
108. Arsenic trioxide is an equipotent inducer of apoptosis in androgen-dependent and androgen-independent LNCaP prostate cancer cell sublines
109. Cytotoxicity of arsenic trioxide in cancer cell lines
110. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
111. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
112. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
113. Toxic effects of metals
114. Heavy metals and heavy-metal antagonists
115. Arsenic trioxide, a novel mitochondriotoxic anticancer agent?
116. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore
117. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
118. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells
119. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia
120. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
121. U.S. multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL)
122. Leukocytosis and the 'retinoic acid syndrome' during induction treatment of acute promyelocytic leukemia with arsenic trioxide
123. The 'retinoic acid syndrome' in acute promyelocytic leukemia
124. UCN-01, a selective inhibitor of protein kinase C from Streptomyces
125. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II Purification, physico-chemical properties, structural determination and biological activities
126. Potent and specific inhibitors of protein kinase C of microbial origin
127. Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors
128. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cipl/WAF1/Sdil in p53-mutated human epidermoid carcinoma A 431 cells
129. Principles of CDK regulation
130. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells
131. Cell cycle regulation of human Weel
132. Chk1 is a target of the anticancer agent UCN-01
133. 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53
134. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells
135. Enhancement of fludarabine and gemcitabine toxicity by UCN-01 in a variety of tumor cell lines
136. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C
137. UCN-01: A potent abrogator of G 2 checkpoint function in cancer cells with disrupted p53
138. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN- 01, a selective protein kinase inhibitor
139. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2
140. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
141. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alphal-acid glycoprotein
142. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alphal-acid glycoprotein in human
143. Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity
144. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms
145. The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10
146. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain
147. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites
148. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity
149. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity
150. Antineoplastic dolastatins: Potent inhibitors of hematopoietic progenitor cells
151. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15
152. Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines
153. Dolastatin 10 and dolastatin 15: Effects of two natural peptides on growth and differentiation of leukemia cells
154. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc
155. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification
156. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1
157. Serine-70 is one of the critical sites for drug-induced bcl-2 phosphorylation in cancer cells
158. The bcl- 2 and 53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma
159. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay
160. Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128)
161. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance
162. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors
163. A phase I, pharmacokinetic/pharmacodynamic study of dolastatin-10 in adult patients with advanced solid tumors
164. Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: Application in a phase 1 clinical trial
165. Dolastatin 10 (dola 10) administered with G-CSF allows substantial escalation of the maximum tolerated dose (MTD) in patients (pts) with advanced solid tumors
166. Phase I study of dolastatin-10 in refractory or relapsed acute leukemia
167. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
168. Advances in the development of farnesyltransferase inhibitors: Substrate recognition by protein farnesyltransferase
169. Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777
170. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI) with potent oral antitumor activity
171. The potential of farnesyltransferase inhibitors as cancer therapeutics
172. Phase I trial of farnesyl-transferase inhibitor, R115777, in advanced cancer
173. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor (FTI) R115777
174. Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers
175. Constitutive and selective expression of basic fibroblast growth factor in human leukemia cell lines
176. The effect of basic and acidic fibroblast growth factors (bFGF and aFGF) on the growth of leukemic blast progenitors in acute myelogenous leukemia
177. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine
178. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
179. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
180. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis
181. Antitumor activity of thalidomide in refractory multiple myeloma
182. Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM)
183. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
184. Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS)
185. Angiogenesis in myelodysplastic syndromes
186. Sideroblastic anemia treated with immunosuppressive therapy
187. Antithymocyte globulin for patients with myelodysplastic syndrome
188. Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele
189. Unusual clinical presentation in a patient with myelodysplastic syndrome, with subsequent hematological remission and suppression of the malignant clone following treatment with cyclosporine A, erythropoietin and granulocyte colony-stimulating factor
190. Long-term improvement of hematopoiesis following cyclosporine treatment in a patients with myelodysplastic syndrome
191. Prolonged transfusion independence and disease stability in patients with myelodysplastic syndrome (MDS) responding to antithymocyte globulin (ATG)
192. Response criteria for clinical trials in the myelodysplastic syndromes: Recommendations from and international working group